We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01155791
Recruitment Status : Terminated
First Posted : July 2, 2010
Last Update Posted : March 15, 2017
Information provided by (Responsible Party):
Sandy Srinivas, Stanford University

Brief Summary:
Selenium, in the form of inorganic Sodium Selenite, may be useful for treating existing prostate cancer. This idea is based on data from our laboratory showing that 1) prostate cancer cells are more sensitive to Selenium (Sodium Selenite)-induced apoptosis than normal prostate epithelial cells, 2) Selenite induces significant growth inhibition of well established prostate cancer tumors in mice at doses that have no detectable toxicity, and 3) Selenite disrupts AR signaling, and that the inhibition of AR expression and activity by Selenite occurs via a redox mechanism involving GSH, superoxide, and Sp1. Altogether, these findings suggest that Selenium may be useful in a variety of potential indications in the natural history of prostate cancer, including both hormone sensitive and castrate resistant prostate cancer, as a single agent, or in combination with radiation, chemotherapy or conventional hormone therapy. Selenite is a potential novel inhibitor of AR expression and function in prostate cancer.

Condition or disease Intervention/treatment Phase
Urologic Neoplasms Prostate Cancer Prostate Cancer Metastatic Disease Drug: Docetaxel Drug: Biosyn Drug: Prednisone Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
Study Start Date : April 2010
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: combination sodium selenite and docetaxel Drug: Docetaxel
IV 75 mg/m2

Drug: Biosyn
IV dosage varies

Drug: Prednisone
5mg, orally

Primary Outcome Measures :
  1. To determine the safety and tolerability of the combination sodium selenite and docetaxel after 4 cycles of combination therapy using the NCI Common Toxicity Criteria v3.0 grading system for adverse events [ Time Frame: after 4 cycles of combination therapy ]
  2. To determine the maximum tolerated dose (MTD) [ Time Frame: 1 cycle ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed adenocarcinoma of the prostate
  2. Castration-resistant prostate cancer requires the following 3 criteria:

    • Failure of first line bilateral orchiectomy or therapy with an LHRH agonist,
    • A rising PSA on 3 consecutive occasions at least 1 week apart (but not limited to the 30 day screening period), AND
    • A castrate level of testosterone (<50ng/dL)
  3. PSA doubling time (PSADT) > 1 months
  4. Failure on docetaxel chemotherapy as defined by a rising PSA .
  5. A minimum PSA of 2 ng/mL
  6. Age >=18 years
  7. Life expectancy greater than 6 months
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or Karnofsky performance status >=80%
  9. Bone metastases will be allowed
  10. The subject has a QTcB (Bazett corrected) or QTcF (Frederica corrected) < 470 msec.
  11. Ability to understand and the willingness to sign a written informed consent document.
  12. Willingness to stay on docetaxel chemotherapy despite rising PSA level.

Exclusion Criteria:1. Radiotherapy for prostate cancer within 28 days prior to Day 1.

2. More than 1 prior chemotherapy

3. Inadequate organ function, as evidenced by any of the following at screening:

  • Absolute neutrophil count (ANC) < 1500/uL
  • Platelet count <= 100 x 10^9/L
  • Total bilirubin >= ULN
  • AST, and/or ALT > 1.5 x the upper limit of normal (ULN) with a concomitant alkaline phosphastase >2.5 X ULN
  • Serum creatinine > 2.0 mg/dL
  • Hemoglobin < 9 g/dL

    4. Men with reproductive potential who do not agree to use an accepted and effective method of contraception during the study treatment period and for at least 3 months after completion of the study treatment.

    5. History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma, squamous-cell carcinoma of the skin, or early-stage bladder cancer

    6. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.

    7. Known or prior treated brain metastases.

    8. History of hypersensitivity to docetaxel

    9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure ,unstable angina pectoris, cardiac arrhythmia, significant vascular disease (e.g. aortic aneurysm, aortic dissection), symptomatic peripheral vascular disease, or psychiatric illness/social situations that would limit compliance with study requirements.

    10. History of myocardial infarction or unstable angina within 6 months prior to study enrollment

    11. History of stroke or transient ischemic attack within 6 months prior to study enrollment 12. The subject is known to be positive for the human immunodeficiency virus (HIV) and is receiving antiretroviral 12. Willingness to stay on docetaxel chemotherapy despite rising PSA level.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01155791

Layout table for location information
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Sandy Srinivas
Layout table for investigator information
Principal Investigator: Dr. Sandy Srinivas Stanford University
Layout table for additonal information
Responsible Party: Sandy Srinivas, Associate Professor, Stanford University
ClinicalTrials.gov Identifier: NCT01155791    
Other Study ID Numbers: PROS0033
SU-05122010-6002 ( Other Identifier: Stanford University )
17356 ( Other Identifier: Stanford IRB )
First Posted: July 2, 2010    Key Record Dates
Last Update Posted: March 15, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Neoplasm Metastasis
Urologic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Neoplastic Processes
Pathologic Processes
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal